SITAGLIPTINE TEVA 100 mg, film-coated tablet 30 tablets
Active ingredients: MALATE DE SITAGLIPTINE, Sitagliptin
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SITAGLIPTINE TEVA 100 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 30 comprimé(s)
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 30 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 2 Nov 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62145198CIP73013669CIP133400930136690Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SITAGLIPTINEcomprimé | 100 mg · un comprimé | FT |
| MALATE DE SITAGLIPTINEcomprimé | 132,92 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: SITAGLIPTINE (PHOSPHATE DE) MONOHYDRATE équivalant à SITAGLIPTINE 100 mg - SITAGLIPTINE (MALATE DE) équivalant à SITAGLIPTINE 100 mg - JANUVIA 100 mg, comprimé pelliculé
